US Stock Insider Trading | NeuroPace disclosed one insider transaction on February 23

K-LinePoet · 2026-02-24T00:06:37+00:00

On February 23, 2026, NeuroPace disclosed that executive Morrell Martha sold 3,412 shares on February 20, with a total transaction amount of approximately $48,900. Recently, several other directors and executives have also engaged in insider trading. NeuroPace is a medical device company focused on epilepsy treatment.

K-LinePoet

2026-02-24 00:06:37

Abstract generation in progress

On February 23, 2026, NeuroPace (NPCE) disclosed an insider trading transaction. Executive Morrell Martha sold 3,412 shares on February 20, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 23, 2026	Executive	Morrell Martha	February 20, 2026	Sell	3412	14.34	$48,900
December 23, 2025	Director	Fischer Frank M, Geiger Uri, Kumar Rakhi, LACOB JOSEPH	December 19, 2025	Buy	3728	16.59	$61,800
December 4, 2025	Executive	Morrell Martha	December 3, 2025	Sell	1338	16.66	$22,300
December 1, 2025	Director	Becker Joel	November 27, 2025	Sell	1126	16.50	$18,600
December 1, 2025	Executive	Morrell Martha	November 27, 2025	Sell	357	16.50	$5,890.50
November 24, 2025	Executive	Morrell Martha	November 20, 2025	Sell	3051	13.50	$41,200
September 22, 2025	Director	Fischer Frank M, Geiger Uri, Kumar Rakhi, LACOB JOSEPH	September 19, 2025	Buy	6223	9.94	$61,900
September 4, 2025	Executive	Morrell Martha	September 3, 2025	Sell	1337	9.36	$12,500
August 28, 2025	Director	Becker Joel	August 27, 2025	Sell	1126	8.88	$9,998.88
August 28, 2025	Executive	Morrell Martha	August 27, 2025	Sell	357	8.88	$3,170.16

[Company Information]

NeuroPace, Inc. was incorporated on November 19, 1997, in Delaware. The company is a medical device company focused on changing the lives of epilepsy patients by reducing or eliminating debilitating seizures.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.